Innovative therapies for sepsis

Area of Science:

• Critical Care Medicine
• Immunology
• Pathophysiology

Background:

• Sepsis and septic shock are significant contributors to patient morbidity and mortality.
• Despite advances in supportive care, mortality rates for sepsis have remained largely unchanged over the past two decades.
• Numerous innovative therapies targeting the inflammatory and coagulation cascades have been explored.

Purpose of the Study:

• To review the challenges and recent advancements in sepsis treatment strategies.
• To evaluate the efficacy of novel therapeutic approaches in clinical trials.
• To discuss reasons for the failure of early sepsis clinical trials and highlight promising recent findings.

Main Methods:

• Review of recent clinical trials in sepsis research.
• Analysis of therapeutic strategies targeting cytokine activation, inflammation, and coagulation.
• Evaluation of outcomes from trials involving corticosteroids, anti-tumour necrosis factor agents, and drotrecogin alfa (rhAPC).

Main Results:

• Most innovative therapies in sepsis research have failed to demonstrate improved survival in clinical trials.
• Potential reasons for trial failures include discrepancies between animal models and human patients, patient heterogeneity, and the complexity of inflammatory pathways.
• Recent trials on corticosteroids, anti-tumour necrosis factor, and drotrecogin alfa (rhAPC) have reported positive results, with drotrecogin alfa being peer-reviewed and published.

Conclusions:

• The development of effective sepsis therapies is hindered by the complexity of the disease and limitations in preclinical models.
• Despite past failures, recent positive trial outcomes, particularly for drotrecogin alfa, offer renewed hope for improving sepsis patient survival.
• Further research and carefully designed clinical trials are crucial to overcome the challenges in treating sepsis and septic shock.